Compare CCD & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCD | VALN |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 662.0M | 653.3M |
| IPO Year | 2014 | 2021 |
| Metric | CCD | VALN |
|---|---|---|
| Price | $24.87 | $6.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 51.9K | ★ 86.1K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.99 | $4.75 |
| 52 Week High | $26.99 | $12.23 |
| Indicator | CCD | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 39.36 | 59.03 |
| Support Level | $23.68 | $5.10 |
| Resistance Level | $24.64 | $7.31 |
| Average True Range (ATR) | 0.42 | 0.21 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 17.34 | 51.19 |
Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.